CureVac (NASDAQ:CVAC – Get Free Report)’s stock price was up 4.7% during mid-day trading on Thursday . The company traded as high as $4.32 and last traded at $4.26. Approximately 356,735 shares were traded during trading, a decline of 79% from the average daily volume of 1,710,864 shares. The stock had previously closed at $4.07.
CureVac Trading Up 2.6 %
The company has a market cap of $934.70 million, a P/E ratio of 7.59 and a beta of 2.50. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The stock’s 50 day moving average is $3.13 and its 200-day moving average is $3.15.
Institutional Investors Weigh In On CureVac
Several institutional investors have recently modified their holdings of CVAC. Private Advisor Group LLC bought a new stake in shares of CureVac in the third quarter worth approximately $30,000. International Assets Investment Management LLC purchased a new stake in CureVac during the 3rd quarter valued at $35,000. Integrated Wealth Concepts LLC purchased a new position in shares of CureVac in the 3rd quarter worth $35,000. Bank of New York Mellon Corp purchased a new stake in CureVac during the second quarter valued at $54,000. Finally, Ballentine Partners LLC lifted its holdings in CureVac by 58.6% in the third quarter. Ballentine Partners LLC now owns 22,755 shares of the company’s stock valued at $67,000 after acquiring an additional 8,406 shares during the period. 17.26% of the stock is owned by hedge funds and other institutional investors.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Stories
- Five stocks we like better than CureVac
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Are Penny Stocks a Good Fit for Your Portfolio?
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
